↓ Skip to main content

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update

Overview of attention for article published in Clinical Pharmacology & Therapeutics, April 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

news
1 news outlet
twitter
1 tweeter

Citations

dimensions_citation
275 Dimensions

Readers on

mendeley
291 Mendeley
Title
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update
Published in
Clinical Pharmacology & Therapeutics, April 2017
DOI 10.1002/cpt.668
Pubmed ID
Authors

JA Johnson, KE Caudle, L Gong, M Whirl-Carrillo, CM Stein, SA Scott, MT Lee, BF Gage, SE Kimmel, MA Perera, JL Anderson, M Pirmohamed, TE Klein, NA Limdi, LH Cavallari, M Wadelius

Abstract

This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2-3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry. This article is protected by copyright. All rights reserved.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 291 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Unknown 290 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 46 16%
Student > Master 42 14%
Researcher 39 13%
Student > Ph. D. Student 35 12%
Student > Doctoral Student 18 6%
Other 54 19%
Unknown 57 20%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 58 20%
Biochemistry, Genetics and Molecular Biology 57 20%
Medicine and Dentistry 49 17%
Agricultural and Biological Sciences 19 7%
Nursing and Health Professions 6 2%
Other 33 11%
Unknown 69 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 January 2020.
All research outputs
#2,199,210
of 16,722,463 outputs
Outputs from Clinical Pharmacology & Therapeutics
#412
of 3,512 outputs
Outputs of similar age
#51,133
of 265,150 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#7
of 32 outputs
Altmetric has tracked 16,722,463 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,512 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,150 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.